Roberto Calle

Roberto Calle

Company: Pfizer

Job title: Executive Director


Roberto Calle is Executive Director with the Internal Medicine Research Unit, Pfizer-Cambridge, where he serves as Clinical Lead for programs across different areas of metabolism. He is a physician-scientist and board-certified endocrinologist with 17 years of experience in drug development at Pfizer Inc, spanning methodology studies, Phase 1, 2, and 3. Roberto received his B.S. in Biology Magna Cum Laude from the University of Puerto Rico and received his MD from the same institution, where he was elected to membership in the Alpha Omega Alpha Medical Honor Society. He trained in Internal Medicine at the University of Michigan and subsequently completed a research fellowship in Endocrinology & Metabolism at Yale University School of Medicine. During his academic careers his research focused on cellular signaling mechanisms mediating insulin release and atrial natriuretic peptide’s modulation of aldosterone secretion. Roberto is currently Co-Chair of the Metabolic Disorders Steering Committee of the Foundation for the NIH (FNIH) Biomarkers Consortium. He is also Co-chair of the Non-Invasive BioMarkers of MetaBolic Liver DiseasE (NIMBLE) program, sponsored by the FNIH-Biomarkers Consortium.

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.